Bacteriology - Genova Diagnostics, Inc.

1 Genova Diagnostics A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic. #34D0655571 Medicare Lic. #34-8475 Patient: SAMPLEPATIENT DOB: Sex: MRN: of Protein Breakdown (Total)(Valerate, Isobutyrate, Isovalerate)Vegetable FibersRareNone - FewMeat FibersInsideOutsideReference RangeNoneNoneAbsorptionReference mg/g< Chain Fatty mg/g< Fat (Total*)Triglycerides* Total values equal the sum of all measurable MarkersReference Range>= SCFAs (Total*)>= * Total values equal the sum of all measurable % %<= % % % %ImmunologyFecal Lactoferrin InsideOutside Reference RangeNegativeNegativeMacroscopicColorMuc usOccult blood BrownNegativeBrownNegativeNegativeNegati ve368-6,266 PathogenPPNon-PathogenNPNo Growth*NG*NGBacteriologyBeneficial BacteriaAdditional BacteriaMycologyLactobacillus species*NGEscherichia coli*NGBifidobacterium4+Klebsiella pneumoniae4+ PPEnterobacter cloacae4+ PPKlebsiella oxytoca4+ PPEnterococcus durans4+ NPCandida species1+ NP2001 CDSA/P (Comprehensive Digestive Stool Analysis/Parasitology) - StoolMethodology.

2 MALDI-TOF MS, Automated and Manual Biochemical Methods, Vitek 2 System Microbial identification and Antibiotic susceptibility, Automated Chemistry, GC-FID, Microscopic Evaluation, ELISA, Ion Selective Electrode, Immunoassay, GCMS Genova Diagnostics A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic. #34D0655571 Medicare Lic. #34-8475 Page 2 Patient: SAMPLE PATIENTID: ParasitologyMicroscopic O&P ResultsMicroscopic O&P is capable of detecting all described gastrointestinal parasites. The organisms listed in the box represent those commonly found in microscopic stool analysis. Should an organism be detected that is not included in the list below, it will be reported in the Additional Results section. For an extensive reference of all potentially detectable organisms, please visit - roundwormsAncylostoma/Necator (Hookworm)

3 Not DetectedAscaris lumbricoidesNot DetectedCapillaria philippinensisNot DetectedEnterobius vermicularisNot DetectedStrongyloides stercoralisNot DetectedTrichuris trichiuraNot DetectedDiphyllobothrium latumNot DetectedCestodes - tapewormsDipylidium caninumNot DetectedHymenolepis diminutaNot DetectedHymenolepis nanaNot DetectedTaenia DetectedTrematodes - flukesClonorchis/Opisthorchis DetectedFasciola buskiNot DetectedHeterophyes/MetagonimusNot DetectedParagonimus DetectedSchistosoma DetectedBalantidium coliNot DetectedProtozoaBlastocystis DetectedChilomastix mesniliNot DetectedCryptosporidium DetectedCyclospora cayetanensisNot DetectedDientamoeba fragilisNot DetectedEntamoeba coliNot DetectedEntamoeba histolytica/disparNot DetectedEntamoeba hartmaniiNot DetectedEntamoeba poleckiNot DetectedEndolimax nanaNot DetectedGiardiaNot DetectedIodamoeba buetschliiNot DetectedCystoisospora DetectedTrichomonads ( Pentatrichomonas)Not DetectedAdditional FindingsWhite Blood CellsNot DetectedCharcot-Leyden CrystalsNot DetectedOther Infectious 3ID: Patient: SAMPLE PATIENTA dditional Tests (if indicated) Genova Diagnostics A.

4 L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic. #34D0655571 Medicare Lic. #34-8475 Parasitology EIA TestsCryptosporidium ResultExpected ResultNegativeNegativeNegativeGiardia lamblia NegativeMethodology: EIAN egativeEntamoeba histoytica NegativePrescriptive AgentsKLEBSIELLA PNEUMONIAERIS-DD*SNI* AcidSCephalothinSCiprofloxacinSTetracycl ineSTrimethoprim/SulfaSNatural AgentsKLEBSIELLA PNEUMONIAELow InhibitionHigh InhibitionBerberineOreganoPlant TanninsUva-UrsiBacterial SensitivityPatient: SAMPLEPATIENT DOB: Sex: MRN: SENB2 RMS 65 Rev 5 Genova Diagnostics A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic. #34D0655571 Medicare Lic. #34-8475 Prescriptive Agents: The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates.

5 * The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.* NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC to published pharmaceutical guidelines for appropriate dosage Agents: In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a substance. The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment.

6 High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared by the Food and Drug AgentsENTEROBACTER CLOACAERIS-DD*SNI* AcidRCephalothinRCiprofloxacinSTetracycl ineSTrimethoprim/SulfaSNatural AgentsENTEROBACTER CLOACAELow InhibitionHigh InhibitionBerberineOreganoPlant TanninsUva-UrsiBacterial SensitivityPatient: SAMPLEPATIENT DOB: Sex: MRN: SENB2 RMS 65 Rev 5 Genova Diagnostics A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic.

7 #34D0655571 Medicare Lic. #34-8475 Prescriptive Agents: The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates. * The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.* NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC to published pharmaceutical guidelines for appropriate dosage Agents: In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a substance.

8 The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared by the Food and Drug AgentsKLEBSIELLA OXYTOCARIS-DD*SNI* AcidSCephalothinSCiprofloxacinSTetracycl ineSTrimethoprim/SulfaSNatural AgentsKLEBSIELLA OXYTOCALow InhibitionHigh InhibitionBerberineOreganoPlant TanninsUva-UrsiBacterial SensitivityPatient: SAMPLEPATIENT DOB: Sex: MRN: SENB2 RMS 65 Rev 5 Genova Diagnostics A.

9 L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic. #34D0655571 Medicare Lic. #34-8475 Prescriptive Agents: The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates. * The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.* NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC to published pharmaceutical guidelines for appropriate dosage Agents: In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a substance.

10 The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared by the Food and Drug AntifungalsCANDIDA SPECIESRIS-DD*SNI*FluconazoleNIVoriconaz oleNINon-absorbed AntifungalsCANDIDA SPECIESLow InhibitionHigh InhibitionNystatinNatural AntifungalsCANDIDA SPECIESLow InhibitionHigh InhibitionBerberineCaprylic AcidGarlicUndecylenic AcidPlant tanninsUva-UrsiYeast SensitivityPatient: SAMPLEPATIENT DOB: Sex: MRN: SENY3 RMS 65 Rev 4 Genova Diagnostics A.